Literature DB >> 2898862

Long-term use of somatostatin analogue SMS 201-995 in the treatment of hypoglycaemia due to nesidioblastosis.

D C Wilson1, D J Carson, R J Quinn.   

Abstract

An infant presented with hypoglycaemia secondary to nesidioblastosis. Subtotal pancreatectomy failed to prevent recurrent post-operative hypoglycaemia. Subcutaneous somatostatin analogue (SMS 201-995) was shown to increase the blood concentrations of glucose and B-hydroxybutyrate while lowering serum insulin levels. Regular use of somatostatin analogue was helpful in long term management without causing significant side effects.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2898862     DOI： 10.1111/j.1651-2227.1988.tb10683.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN： 0001-656X


  6 in total

1.  Tolerance to somatostatin analogue in a preterm infant with islet cell dysregulation syndrome.

Authors:  J M Hawdon; M P Ward Platt; W H Lamb; A Aynsley-Green
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

Review 2.  Clinical use of the long acting somatostatin analogue octreotide in pediatrics.

Authors:  M T Tauber; A G Harris; P Rochiccioli
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

3.  Surgical treatment of hyperinsulinaemic hypoglycaemia in infancy and childhood.

Authors:  L Spitz; R K Bhargava; D B Grant; J V Leonard
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

Review 4.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.

Authors:  A G Harris
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 5.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 6.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.